Compare Amylx Pharmaceuticals Inc (AMLX) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs MPLX LP — how do they compare? Amylx Pharmaceuticals Inc trades at $24.03 (market cap $2.64B), while MPLX LP trades at $59.91 (market cap $60.12B). The key difference: MPLX LP is far larger — about 22.8× Amylx Pharmaceuticals Inc's market cap, and MPLX LP pays a 7.26% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MPLX | |
|---|---|---|
Market Cap | $2.64B | $60.12B |
Sector | Health | Technology |
52-Week High | $24.19 | $60.51 |
52-Week Low | $7.82 | $47.80 |
Enterprise Value | $2.39B | $85.22B |
Dividend Yield | — | 7.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
MPLX trades at $59.75, up 1.79% today, with a bullish technical signal from moving averages and support near $59. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 and Q2 2026 EPS missed expectations. Recent news highlights a $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) and solid Q2 performance driven by natural gas and NGL volume growth.
Outlook remains positive with a 67.86% analyst buy rating and $61.50 consensus price target, offering potential upside. Key opportunities include fee-based revenue stability and dividend growth, while risks involve higher capital spending and execution challenges on growth projects. The stock presents a balanced profile for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
